Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexxar in Relapsed/Refractory DLCL
NCT00490009Phase 2Completed
- Start
- Sep 2004
- Primary completion
- Apr 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tositumomab in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Clinical Response Rate at 6 years. Started Sep 2004; status: completed.
02
Drugs
tositumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00490009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490009.